# A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

> **NCT02426034** · PHASE4 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 2004 (actual)

## Conditions studied

- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** ApatinibTablets

## Key facts

- **NCT ID:** NCT02426034
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-15
- **Primary completion:** 2020-05-29
- **Final completion:** 2020-09-03
- **Target enrollment:** 2004 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426034, "A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02426034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*